A University of California author or department has made this article openly available. Thanks to the Academic Senate’s Open Access Policy, a great many UC-authored scholarly publications will now be freely available on this site. Let us know how this access is important for you. We want to hear your story!
http://escholarship.org/reader_feedback.html

Peer Reviewed

Title:
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.

Journal Issue:
PloS one, 7(10)

Author:
Dellinger, Ryan W
Matundan, Harry H
Ahmed, Amelia S
Duong, Priscilla H
Meyskens, Frank L Jr

Publication Date:
October 22, 2012

Series:
UC Irvine Previously Published Works

Permalink:
http://escholarship.org/uc/item/2f85w3vb

Keywords:
Antineoplastic Agents: pharmacology, Cell Line, Tumor, Dacarbazine: analogs & derivatives, Doxorubicin, Drug Resistance, Neoplasm: drug effects, physiology, Epirubicin, Gene Expression Regulation: drug effects, Gene Knockdown Techniques, Glucuronosyltransferase: genetics, metabolism, Humans, Indoles, Melanocytes: metabolism, Melanoma: metabolism, Sulfonamides, alamethicin, antineoplastic agent, doxorubicin, epirubicin, glucuronosyltransferase, glucuronosyltransferase 2B10, glucuronosyltransferase 2B15, glucuronosyltransferase 2B7, temozolomide, unclassified drug, vemurafenib, antineoplastic activity, article, cancer growth, cancer resistance, cell stimulation, controlled study, cytotoxicity, enzyme activity, glucuronidation, human, human cell, melanocyte, melanoma, melanoma cell, newborn, protein expression, protein function, Antineoplastic Agents, Cell Line, Tumor, Dacarbazine, Doxorubicin, Drug Resistance, Neoplasm, Epirubicin, Gene Expression Regulation, Gene Knockdown Techniques, Glucuronosyltransferase, Humans, Indoles, Melanocytes, Melanoma, Sulfonamides

Local Identifier(s):
PubMed ID: 23110092
Abstract:
The UDP-glucuronosyltransferase (UGT) family of enzymes plays a vital role in the detoxification of carcinogens as well as clearance of anti-cancer drugs. In humans, 19 UGT family members have been identified and are expressed in a tissue specific manner throughout the body. However, the UGTs have not been previously characterized in melanocytes or melanoma. In the present study, UGT2B7, UGT2B10, and UGT2B15 were identified as being normally expressed in human melanocytes. The same three UGT family members were also expressed in the primary melanoma cell line WM115. No UGT expression was detected in another primary melanoma cell line, WM3211, or in any metastatic melanoma cell line examined. These results suggest that UGT expression is lost during melanoma progression. Treatment of WM3211 or metastatic melanoma cell lines with anti-cancer agents (including vemurafenib) induced expression of UGT2B7, UGT2B10 and UGT2B15 demonstrating that melanoma cells retain the ability to re-express these same three UGTs. The corresponding increase in glucuronidation activity in melanoma cells following anti-cancer treatment was also observed. Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs. However, knockdown of UGT2B7 had no effect on temozolomide toxicity. Taken together, these results clearly demonstrate a role for UGTs in melanoma etiology. Since the UGTs are drug metabolism enzymes, we propose that re-expression of the UGTs constitutes a previously unsuspected mechanism for intratumoral drug resistance in melanoma.

Copyright Information:
Anti-Cancer Drugs Elicit Re-Expression of UDP-Glucuronosyltransferases in Melanoma Cells

Ryan W. Dellinger1,2*, Harry H. Matundan3, Amelia S. Ahmed3, Priscilla H. Duong3, Frank L. Meyskens Jr.1,2,3,4

1 Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, United States of America, 2 Department of Medicine, University of California Irvine, Irvine, California, United States of America, 3 Department of Biological Chemistry, University of California Irvine, Irvine, California, United States of America, 4 Department of Public Health, University of California Irvine, Irvine, California, United States of America

Abstract

The UDP-glucuronosyltransferase (UGT) family of enzymes plays a vital role in the detoxification of carcinogens as well as clearance of anti-cancer drugs. In humans, 19 UGT family members have been identified and are expressed in a tissue specific manner throughout the body. However, the UGTs have not been previously characterized in melanocytes or melanoma. In the present study, UGT2B7, UGT2B10, and UGT2B15 were identified as being normally expressed in human melanocytes. The same three UGT family members were also expressed in the primary melanoma cell line WM115. No UGT expression was detected in another primary melanoma cell line, WM3211, or in any metastatic melanoma cell line examined. These results suggest that UGT expression is lost during melanoma progression. Treatment of WM3211 or metastatic melanoma cell lines with anti-cancer agents (including vemurafenib) induced expression of UGT2B7, UGT2B10 and UGT2B15 demonstrating that melanoma cells retain the ability to re-express these same three UGTs. The corresponding increase in glucuronidation activity in melanoma cells following anti-cancer treatment was also observed. Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs. However, knockdown of UGT2B7 had no effect on temozolomide toxicity. Taken together, these results clearly demonstrate a role for UGTs in melanoma etiology. Since the UGTs are drug metabolism enzymes, we propose that re-expression of the UGTs constitutes a previously unsuspected mechanism for intratumoral drug resistance in melanoma.

Citation: Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL Jr (2012) Anti-Cancer Drugs Elicit Re-Expression of UDP-Glucuronosyltransferases in Melanoma Cells. PLoS ONE 7(10): e47696. doi:10.1371/journal.pone.0047696

Editor: Keiran Smalley, The Moffitt Cancer Center & Research Institute, United States of America

Received July 16, 2012; Accepted September 17, 2012; Published October 22, 2012

Copyright: © 2012 Dellinger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by generous support from the Oxnard and Waltmar Foundations as well as grants from the National Institutes of Health National Cancer Institute [P30CA62330] to FLM and a cancer biology training grant [T32CA009054] provided salary support for RWD for this work. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: rdelling@uci.edu

Introduction

The UGT family of enzymes catalyzes the glucuronidation of a wide range of xenobiotic and endogenous compounds. UGTs conjugate a glucuronic acid moiety to their substrates, altering the biological properties of the substrate and enhancing its excretion in urine or bile [1,2]. In general, glucuronidation converts substrates into less bioactive, more water soluble products facilitating their removal from the body. In this manner, the UGTs are integrally involved in the detoxification of many carcinogens, the clearance of drugs and the metabolism of a variety of endogenous substrates such as bilirubin, steroid hormones and bioactive lipids [1,2]. There are 19 functional human UGTs classified into three subfamilies based upon structural and amino acid sequence homology, UGT1, UGT2 and UGT2B [2].

The UGTs are membrane bound enzymes largely localized to the endoplasmic reticulum [1,3]. Substrate specificity varies greatly between family members, with broad overlap, and their substrate specificity can be altered by posttranslational modifications such as phosphorylation [4]. Although UGTs are primarily expressed in liver, they also play vital roles in other tissues in the body. For example, UGT2B15 and UGT2B17 are expressed in the prostate where they regulate local androgen levels through glucuronidation [5] and UGT1A10 and UGT2B7 are expressed in the breast where they regulate estrogens [6]. There is also ample evidence that the UGTs play important roles in the aerodigestive tract, gastrointestinal tract, lung, colon, bladder, kidneys and brain [7,8,9,10,11]. However, the role of the UGTs in skin, the largest organ in the body, has yet to be investigated.

Melanoma is one of the fastest growing tumor types in the United States and the number of cases worldwide has doubled in the past 30 years [12]. Melanoma, which arises from melanocytes, is an extremely aggressive tumor that invades the vascular and lymphatic systems to form tumors elsewhere in the body [12,13,14]. Melanoma is a particularly resilient cancer, accounting for only 4% of all skin cancers but responsible for 80% of skin cancer deaths [15]. Further, only 14% of patients with metastatic melanoma survive for 5 years [15].

Systemic therapy approaches have achieved minimal success against metastatic melanoma resulting in only a few FDA-approved treatments [16]. Interferon-α2b, interleukin-2 and temozolomide have all demonstrated limited efficacy with response rates generally under 15% in the short term with no
clear effect on melanoma-related mortality [16]. However, the recent success of the specific BRAF mutant inhibitor vemurafenib in a Phase 1 clinical trial is very promising [17]. An estimated progression free survival of 7 months was reported among all patients harboring the BRAF V600E mutation [17], which is present in approximately 50% of all melanomas [18]. However, the excitement for vemurafenib as a single agent has been tempered somewhat since acquired resistance is already being observed [17]. Thus, understanding the mechanism(s) of resistance to chemotherapy that melanoma cells employ is paramount to combating this deadly disease.

The goal of the present study was to characterize the expression and function of UGTs in melanocytes and melanoma and to examine the potential role of UGTs in drug resistance. Evidence presented here reveals three UGT family members, UGT2B7, UGT2B10 and UGT2B15, as being normally expressed in human melanocytes isolated from neonatal foreskins. The same three UGTs were found to be expressed in the primary melanoma cell line WM115. Interestingly, no UGT expression was observed in another primary melanoma cell line, WM3211, or in any of the three metastatic melanoma cell lines examined, suggesting that UGT expression is lost during melanoma progression. However, treatment of melanoma cells with anti-cancer agents results in re-expression of these same three UGTs. This novel re-expression of UGTs in melanoma is investigated further herein.

**Materials and Methods**

**Reagents and Cell Culture**

Temozolomide, adriamycin, epirubicin and alamethicin were obtained from Sigma. Vemurafenib was purchased from Selleck (Houston, TX). Normal human melanocytes were isolated from de-identified newborn foreskin from circumcision surgery in accordance with a protocol approved by UC Irvine's Internal Review Board. In accordance with this approved protocol there is no recruitment of subjects, only discarded circumcision tissue is collected. No identifying information is collected regarding this tissue that would otherwise be discarded. Melanocytes were isolated as previously described [19,20] and cultured in MCDB153 media supplemented with 2% fetal bovine serum, 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate and 0.15% bovine pituitary extract. The melanoma cell lines WM115, WM3211, Lu1205, SKmel28 and A375 were cultured as described previously [21,22,23]. Only WM3211 has WT B-Raf, all others harbor V600E mutations. All cell lines tested negative for mycoplasma.

**Total RNA Isolation, Reverse Transcription and PCR**

Total RNA was isolated from cells using the Arum total RNA mini Kit (BioRad) according to companies provided protocol. RNA was quantitated using a NanoDrop 1000 (Thermo/Fisher) cDNA was then made from 1.0 μg of RNA using the iScript Reverse Transcription Kit (BioRad) according to standard protocols. PCR was then performed using a Quick load Taq polymerase. The following protocol: Step 1 = 94°C for 2 min; Step 2 (40 cycles) = 94°C for 30 Sec, 55°C for 30 Sec, 68°C for 1 min; Step 3 = 68°C for 10 min. Table S1 in supplementary data lists the primers used to amplify individual UGT family members.

**Real-Time PCR**

To analyze UGT mRNA expression levels in melanoma cells real-time PCR was performed as previously described [3,24]. Briefly, pre-designed TaqMan Gene Expression Assays (Applied Biosystems ID’s Hs02393351_s1 for UGT2B4; Hs00426592_m1 for UGT2B7; Hs02556292_s1 for UGT2B10; Hs00900769_g1 for UGT2B15 and Hs99999905_m1 for GAPDH) were used according to manufacturer’s protocol. Real-time PCR was performed using a total volume of 20 μl containing 30 ng of cDNA using GAPDH as the normalizing ‘housekeeping’ gene. Real-time PCR was performed on a CFX96 Real-Time PCR machine (BioRad). Reported mRNA expression values are the average of at least 3 independent experiments with standard deviation.

**shRNA**

Ready-cloned shRNA targeted against UGT2B7 and control empty expression vectors were purchased Origene. Each shRNA vector was transfected into WM115 cells using the BioT transfection agent (Bioland Scientific) according to manufacturer protocols and stable expression was selected for by addition of puromycin (Invivogen).

**MTT Assay**

To determine the effects of drugs on cell proliferation we performed 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) assays (Sigma Aldrich). Briefly, cells were plated overnight at 2000–4000 cells/well (depending on cell doubling times) in 96 well plates, and treated with either adriamycin, epirubicin, or temozolomide at serial dilutions of the drug. After the third day post-treatment, MTT diluted in dye-free media is added to each well and incubated for 3 hrs. Once the MTT is metabolized by actively proliferating cells into water insoluble formazan then, dimethylsulfoxide (Sigma Aldrich) is added and colorimetric changes are analyzed and quantified with a spectrophotometer at 590 nm. Results from MTTs were analyzed using Graphpad Prism where the dosage of the drug versus its effect on proliferation is graphed; a non-linear regression curve using the sigmoidal dose-response equation was fitted onto the graph and the half-maximal inhibitory concentration (IC50) is obtained. Reported IC50 values are the average of at least 3 independent experiments with standard deviation.

**UGT Activity Assay**

UGT activity was examined using the UGT-Glo assay (Promega) according to manufacturer protocols. Cell homogenates were prepared by re-suspending pelleted cells in Tris-buffered saline (25 mM Tris base, 138 mM NaCl and 2.7 mM KCl; pH 7.4) and subjecting them to three rounds of freeze-thaw prior to homogenization using a glass dounce homogenizer. Cell homogenates (5-20 mg protein/ml) were stored at −70°C in 100 μl aliquots. Total cell homogenate protein concentrations were determined using the BCA assay from Pierce Biotechnology (Rockford, II) after protein extraction using standard protocols. Human liver microsomes (Xenotech, Lenexa, KS) were used as a positive control. Homogenates were incubated with alamethicin for 10 minutes on ice. Each reaction consisted of 50 μg homogenate, UGT-Glo buffer, 50 μM UGT Multienzyme Substrate and water to a total of 30 μl. Then either 10 μl of water or 10 μl 16 mM UDPGA (final concentration 4 mM) was added. Each of these reactions was done in triplicate (total of 6 reactions for each homogenate). Reactions were then incubated at 37°C for 90 min. Only the reactions with the co-substrate UDPGA added can glucuronidate substrate. After 90 min, 40 μl of Luciferin Detection Reagent plus D-Cysteine is added to all wells and the luminescent signal is allowed to stabilize at room temperature for 20 min. Plate was then read on a luminometer (Turner Biosystems).
modulus microplate). As a negative control one set of six reactions was performed without any UGTs present. The UGT Multienzyme Substrate will generate luminescence, but the glucuronidated UGT multienzyme substrate will not. Thus, the average of the triplicate reactions with the co-substrate UDPGA is subtracted from the average of the triplicate reactions without UDPGA to determine UGT activity. Graphs are the composite of multiple independent experiments with standard deviation.

Results

UGT Expression in Human Melanocytes and Melanoma

While UGT expression has previously been reported in the skin [25], UGT expression in melanocytes had not been specifically addressed. In the present study, human melanocytes isolated from de-identified neonatal foreskins were analyzed for UGT expression by RT-PCR. Primer sets designed for individual UGT2B family members were used as well as one common primer set to detect any UGT1A family member. The UGT2As were not measured as they are largely found in the olfactory system [26]. As shown in Figure 1A, UGT2B7, UGT2B10 and UGT2B15 were found to be expressed in human melanocytes. The PCR products indicated by the black arrows (Figure 1A) ran at the predicted sizes, were excised and individual UGT sequences were confirmed. The band in the UGT2B4 lane (Figure 1A, Lane 1) was also excised and determined to be UGT2B7 by sequencing. This is not too surprising as the UGT2B family members share high homology. In fact, UGT2B4 and UGT2B7 share greater than 90% identity at the DNA level and strategies for specific primers is difficult. As a control, RT-PCR was performed using liver RNA to demonstrate that the UGT primers sets were functional and show predicted sizes for each UGT amplicon (Figure 1B). Expression of these same three UGT family members was also observed in human melanocytes from a second de-identified neonatal foreskin (Table 1; NOTE that the numbers 322 and 423 simply denote dates foreskin was obtained from Caucasian infants). Next, UGT expression was examined in several primary and metastatic melanoma cell lines by RT-PCR. Consistent with the UGT expression pattern observed in melanocytes, the primary melanoma cell line WM1115 exhibited only UGT2B7, UGT2B10 and UGT2B15 expression (Figure 1C). Due to the high homology of family members, and similar to Figure 1A, the ‘UGT2B1’ band in Figure 1C was determined to be UGT2B7 after DNA sequencing. Also, the upper band in the UGT1A lane was excised and sequenced (although it was smaller than expected size) and was determined not to be any UGT family member. No UGT expression was observed in another primary melanoma cell line, WM3211 (Figure 1D), or in any of the three metastatic melanoma cell lines examined (Summarized in Table 1; Depicted in Figure S1). These results suggested that UGT expression is lost during melanoma progression.

In order to improve sensitivity and specificity of UGT mRNA detection, TaqMan gene expression assays were used for the rest of this report. These assays have been optimized to be specific for individual UGTs using a probe as well as a primer set. To illustrate this point, and re-affirm that UGT2B7 is present in melanocytes as opposed to UGT2B4, real-time PCR utilizing TaqMan assays was performed on melanocyte cDNA. Figure 1E clearly shows that UGT2B7 is indeed expressed in human melanocytes and UGT2B4 was not detected.

Re-expression of UGTs in Melanoma in Response to Anti-cancer Drugs

Considering that the UGTs are phase II metabolism enzymes and one of their major functions systematically is to eliminate drugs, we examined if the UGTs might play a role in inherent resistance of melanoma cells to chemotherapeutic agents. Thus, the melanoma cell line WM3211 was treated with various anti-cancer agents and UGT expression was assayed by real-time PCR. WM3211 was chosen for these experiments since it has no detectable UGT expression as determined by RT-PCR (Figure 1D).

First we treated WM3211 cells with temozolomide, which is currently indicated for treatment of metastatic melanoma. A dose of 100 μM was chosen for this experiment since published reports for temozolomide treatment of cell culture commonly use a minimum of 100 μM [27,28]. As shown in Figure 2a, UGT2B7, UGT2B10 and UGT2B15 were re-expressed in WM3211 cells in response to temozolomide. Interestingly, no other UGTs were induced (data not shown), only the three UGT family members that are normally expressed in melanocytes (Table 1). The induction of UGT expression in response to temozolomide behaved in a time-dependent manner with maximal expression peaking at 8 Hrs after treatment (Figure 2A). For all three UGTs their expression declines after 8 Hrs, but their expression is still elevated 24 Hrs after treatment (Figure 2A).

To elucidate if the re-expression of these three UGT family members was specific for temozolomide or if this observed response may be a general mechanism for melanoma to defend itself against chemotherapeutics, the anti-cancer agents adriamycin and epirubicin were also examined. These two compounds were selected since they are closely related anthracyclines that are commonly used to treat various types of solid tumors although melanoma has proven to be resistant [29,30]. Furthermore, epirubicin is known to be metabolized primarily by UGT2B7 [31] while the metabolism of adriamycin is much more complex and involves several different Phase II enzymes (including UGTs) and ABC transporters [30]. WM3211 melanoma cells were either untreated or treated with 0.1, 1.0 or 10 μM adriamycin (Figure 2A) or epirubicin (Figure 2B) and UGT expression was examined by real-time PCR after 8 Hrs. In both cases UGT2B7, UGT2B10 and UGT2B15 were observed to be re-expressed. Similar to temozolomide, no other UGT family member was induced (data not shown). Time courses examining UGT expression following treatment of WM3211 cells with 1.0 μM adriamycin (Figure 2B) or 0.1 μM epirubicin (Figure 2C) were then carried out. In both cases UGT2B7, UGT2B10 and UGT2B15 are induced in a time dependent manner, with the highest expression observed at 24 Hrs.

Re-expression of UGT2B7, UGT2B10 and UGT2B15 in Metastatic Melanoma Cells in Response to Epirubicin and Vemurafenib

To ensure that the observed induction of UGTs was not limited to WM3211 cells, two metastatic melanoma cell lines (SKmel28 and A375) were examined for induction of UGT2B7, UGT2B10 and UGT2B15 in response to epirubicin. Time courses examining UGT expression following treatment of SKmel28 (Figure 3A) or A375 (Figure S3) with 0.1 μM epirubicin were then carried out. Once again, induction of all 3 UGTs was observed in both of these metastatic melanoma cell lines with maximal expression at 24 Hrs. Furthermore, since resistance has been observed in clinical trials with the promising new drug vemurafenib, we examined if the UGTs could be induced following vemurafenib treatment.
SKmel28 cells, which harbor the BRAF V600E mutation, were treated with 1 μM vemurafenib, collected at 0, 8, 16 and 24 Hrs post treatment and assayed for UGT expression levels. As shown in Figure 3B, UGT2B7, UGT2B10 and UGT2B15 were all induced in response to vemurafenib.

Increased Glucuronidation in Melanoma Cells Following Treatment with an Anti-cancer Agent

After demonstrating that UGTs can be re-expressed in melanoma cells following treatment with anti-cancer agents, the obvious question was whether UGT activity was restored as well. Therefore, glucuronidation was examined using the UGT-Glo Assay in melanoma cell lines that lack UGT expression and compared to the same cell lines after treatment with epirubicin. This assay employs a UGT Multienzyme Substrate which reacts with the luciferin detection reagent to give light that can be quantitated on a luminometer. However, if the substrate is glucuronidated then it will no longer react with the luciferin detection reagent to give light. Thus, two reactions are set up per sample, one with the co-substrate UDPGA and the other without. Only the reaction with the UDPGA will produce glucuronidated substrate if UGTs are present and active. In this manner the total UGT activity for the sample can be quantified by the difference in emitted light between the two reactions.

First, the primary melanoma WM3211 cells were examined for UGT activity. Cells were either left untreated (UN) or treated with

### Table 1. UGT mRNA expression in melanocytes and melanoma.

| UGT     | Melanocytes | WM115 | WM3211 | Lu1205 | SKmel28 | A375 |
|---------|-------------|-------|--------|--------|---------|------|
| UGT2B4  | ND          | ND    | ND     | ND     | ND      | ND   |
| UGT2B7  | +           | +     | +      | ND     | ND      | ND   |
| UGT2B10 | +           | +     | +      | ND     | ND      | ND   |
| UGT2B11 | ND          | ND    | ND     | ND     | ND      | ND   |
| UGT2B15 | +           | +     | +      | ND     | ND      | ND   |
| UGT2B17 | ND          | ND    | ND     | ND     | ND      | ND   |
| UGT2B28 | ND          | ND    | ND     | ND     | ND      | ND   |
| UGT1A   | ND          | ND    | ND     | ND     | ND      | ND   |

ND = Not Detected.
doi:10.1371/journal.pone.0047696.t001
Figure 2. Re-expression of UGT2B7, UGT2B10 and UGT2B15 in WM3211 cells in response to anti-cancer agents. Predesigned Taqman gene expression assays were used to visualize individual UGT expression by real-time PCR following treatment of WM3211 cells with (A) 100 μM temozolomide, (B) 1.0 μM adriamycin or (C) 0.1 μM epirubicin. In all cases, UGT2B7, UGT2B10 and UGT2B15 expression was examined for the indicated anti-cancer agent at 0, 8, 16 and 24 hrs post treatment. * indicates different scale for y-axis. doi:10.1371/journal.pone.0047696.g002

Figure 3. Re-expression of UGTs in SKmel28 cells in response to epirubicin and vemurafenib. Predesigned Taqman gene expression assays were used to visualize individual UGT expression by real-time PCR following treatment of SKmel28 cells with (A) epirubicin or (B) vemurafenib. Time course of UGT2B expression following epirubicin (100 nM) or vemurafenib (1 μM) treatment was examined at 0, 8, 16 and 24 hrs. * indicates different scale for y-axis. ND = not detected. doi:10.1371/journal.pone.0047696.g003
epirubicin at indicated concentrations. Cells were harvested 24 hrs later and assayed for UGT activity. As shown in Figure 4A, UGT activity was increased in response to epirubicin treatment as compared to untreated cells. Interestingly, there was some basal glucuronidation activity in the untreated WM3211 cells indicating that UGTs are expressed in this cell line, but at levels below the detection of our RT-PCR experiment (Figure 1D). Human liver microsomes were used as a positive control as they have very high concentrations of UGTs and there was no homogenate present in the negative control to account for any background signal. Similar results were observed when this experiment was repeated for two metastatic melanoma cell lines, SKmel28 (Figure 4B) and A375 (Figure 4C). In both of these cell lines UGT activity was dramatically increased after treatment with epirubicin. In contrast to WM3211 cells, neither metastatic cell line exhibited UGT activity in the absence of treatment. Once again human liver microsomes were used as a positive control and the negative control lacked cell homogenate.

**UGT2B7 Knockdown Sensitizes WM115 Melanoma Cells to Anti-cancer Drugs**

To ascertain the functional contribution of glucuronidation to melanoma resistance, UGT2B7 was knocked down in WM115 cells. shRNA directed against UGT2B7 was stably transfected into WM115 cells. This cell line was named WM115-2B7KD. Real-time PCR was then performed to confirm that UGT2B7 mRNA levels had been reduced. Figure 5A clearly shows that UGT2B7 mRNA levels in the WM115-2B7KD cell line was ~60% less than that of WM115 cells stably transfected with empty vector (WM115-pRS). Next, half maximal inhibition concentrations (IC₅₀) as determined by MTT assays, were performed to examine if knockdown of UGT2B7 sensitized WM115 cells to anti-cancer treatment. IC₅₀ values for WM115-2B7KD were determined and compared to WM115-pRS (stable cell line made with empty vector as control) and the parental cell line against temozolomide, Adriamycin and epirubicin. Consistent with a role for glucuronidation in melanoma resistance, WM115-2B7KD was found to have a significantly lower (p<0.01) IC₅₀ value for Adriamycin and epirubicin treatment as compared to both WM115 and WM115-pRS (Figure 5B) indicating that, indeed, knockdown of

![Figure 4. Induction of UGT activity by epirubicin](image-url)

Glucuronidation activity was examined by the UGT-Glo Assay using 50 μg of homogenate per reaction in three melanoma cell lines; (A) WM3211 (B) SKmel28 and (C) A375 without treatment and compared to treatment with epirubicin (EPI) at the indicated concentrations for 24 hrs. (−) indicates a negative control in which no homogenate was present. (+) indicates use of human liver microsomes (known to have high concentrations of almost all UGT family members) as a positive control.

doi:10.1371/journal.pone.0047696.g004
UGT2B7 sensitizes melanoma cells to these anti-cancer drugs. No effect on IC₅₀ values was observed for temozolomide or vemurafenib treatment on the WM115-2B7KD cell line compared to the two control cell lines (Figure 5B).

If knocking down one UGT by ~60% sensitized melanoma cells to adriamycin and epirubicin then it stands to reason that the IC₅₀ for WM3211 melanoma cells (which lack UGT expression) would be significantly lower than WM115 parental cells (which have UGT expression). Thus, we compared the IC₅₀ for WM115 and WM3211 directly for these drugs. As predicted, WM3211 cells were 7-fold and 9-fold more sensitive to adriamycin and epirubicin, respectively (Figure 5C).

Discussion

The role of UGTs in melanoma etiology had not been investigated previously despite the UGTs being a major clearance mechanism for anti-cancer agents. In the present study UGT2B7, UGT2B10 and UGT2B15 were identified as being normally expressed in human melanocytes. The same three UGTs were found to be expressed in the primary melanoma cell line WM115. However, no UGT expression was detected in another primary melanoma cell line, WM3211, or in any of the three metastatic melanoma cell lines examined indicating that UGT expression is lost during melanoma progression. Interestingly we demonstrate that UGT2B7, UGT2B10 and UGT2B15 can be re-expressed in melanoma cells in response to the anti-cancer agents. The corresponding increase in UGT activity was also demonstrated following treatment. Thus, re-expression of the UGTs would presumably protect the cancer cells against anti-cancer drugs through enhanced metabolism and subsequent clearance. Importantly, these observations were consistent in both B-Raf wild type melanoma cells (WM3211) and B-Raf mutant cell lines (A375 and SKme120).

Unfortunately, no commercially available antibody has been shown to detect endogenous UGT2B protein and, accordingly, our attempts to visualize endogenous UGT2B protein were unsuccessful. This is most likely due to the fact that UGTs are membrane bound, insoluble proteins. Accordingly, no full length human UGT has been purified and/or crystallized. In fact, the only crystal structure reported for a human UGT is the C-terminal half of UGT2B7 since the N-terminal half had to be cut off to solubilize the protein [32]. The vast majority of published UGT westerns are cell lines (usually insect) that are overexpressing recombinant UGTs. Further, a recent report clearly demonstrates that a large percentage of these overexpressed, recombinant UGTs are inactive [33]. One can easily imagine that the recombinant UGT proteins that are visible on westerns are not fully mature, active enzymes. Conversely, fully mature, active UGTs may not be visible on westerns even when overexpressed. Thus, consistent...
Re-Expression of UGTs in Melanoma

with several prior publications in the UGT field, the present study focused on mRNA expression of the UGT2B family members coupled with analysis of UGT activity. We utilized RNA interference and glucuronidation assays to examine the role of UGT2B7 on melanoma cell survival [1,3,24,34,35,36,37].

To test the role of glucuronidation in melanoma drug resistance directly, UGT2B7 was knocked down in WM115 cells, the only melanoma cell line we have identified with UGT expression thus far. Knockdown of UGT2B7 sensitized melanoma cells to epirubicin and adriamycin treatment, but had no effect on temozolomide or vemurafenib treatment. These results provide proof of principle that glucuronidation is involved in melanoma drug resistance in vitro. The most logical assumption is that UGT2B7 glucuronidates epirubicin and adriamycin metabolites directly resulting in its clearance before these drugs can exert their toxicity. This is consistent with prior reports that epirubicin is primarily metabolized by UGT2B7 [31] and that glucuronidation is also involved in adriamycin clearance [30]. The observation that the toxicity of temozolomide and vemurafenib was unchanged after UGT2B7 knockdown was not completely unexpected since UGTs have never been implicated in the metabolism of these drugs.

It is important to note that these experiments were done using a UGT2B7 knock down cell line, thus there was still some UGT2B7 present. Furthermore, UGT2B10 and UGT2B15 are still present. The effect of complete loss of UGT2B7 activity (or all UGT activity) would be predicted to have an even greater impact on the sensitization of melanoma to these anthracyclines. Moreover, the individual contributions of each UGT in melanoma survival warrants further investigation as do the underlying mechanism(s) controlling UGT silencing and re-expression in melanoma.

Although this is the first demonstration of UGT2B family members being induced in response to anti-cancer agents in cancer cells, this result is consistent with another report in which UGT1A1 and UGT1A10 expression levels were induced in response to the anti-cancer agent irinotecan in a lung cancer cell line [38]. The authors of that manuscript also demonstrated that the increased levels of UGT1A1 and UGT1A10 increased resistance of lung cancer cells to irinotecan [38]. More recently, another study demonstrated induction of UGT1A1 and UGT1A7 by irinotecan in colon cancer cells [39]. Thus, further investigation is warranted into the role of the UGTs as a general mechanism for intratumoral defense in human cancers.

With the novel demonstration that glucuronidation is involved in melanoma etiology and that active UGTs can be re-expressed in response to anti-cancer agents in a dose and time dependent manner, any future melanoma treatment strategy must account for intratumoral glucuronidation. This is of particular importance if the drug is a known UGT substrate. Inclusion of a UGT inhibitor as part of a cocktail to eliminate the contribution of glucuronidation to intratumoral resistance may be a viable strategy. In support of this idea, one previous study demonstrated that valproic acid can sensitize A375 metastatic melanoma cells to epirubicin [40]. What the authors did not know (or at least did not convey) is that valproic acid is used as a competitive inhibitor for UGT2B7 [41]. Thus, addition of valproic acid most likely sensitized A375 cells to epirubicin by competitively inhibiting the glucuronidation activity of the re-expressed UGT2B7.

Great strides have been made recently regarding our understanding of melanoma resistance thanks to recent intense efforts to understand the acquired resistance to vemurafenib observed in the clinic. These collective efforts have yielded a wealth of information (reviewed nicely in [42]). Several independent labs have demonstrated that melanoma can acquire resistance to vemurafenib in various ways, including mutation of NRAS, upregulation of CRAF or ARAF, redundant PI3-Kinase signaling or activation of COT [42]. Clearly, melanoma has a multitude of acquired resistance schemes it can employ and we humbly submit that induction of the UGT2Bs is another piece to an extraordinary puzzle. Further, now that this vemurafenib has been approved for melanoma treatment in the United States and Europe, the race is on to find the most effective combinatorial treatment to overcome this acquired resistance and combat this deadly disease. To be clear, we do not advocate that re-expression of the UGTs in melanoma in response to vemurafenib constitutes a mechanism of resistance to this drug per se, but we do argue that the ideal candidate to use in combination with vemurafenib should not be a UGT2B substrate.

In summary, we have identified three UGTs as being normally expressed in melanocytes and their expression appears to be lost during melanoma progression. In response to anti-cancer drugs, these same three UGTs are re-expressed in melanoma cells. The corresponding increase in glucuronidation was also observed and, thus, we propose that this re-expression constitutes an intratumoral defense mechanism involved in melanoma resistance to anti-cancer drugs. This hypothesis is strengthened by demonstration that knockdown of UGT2B7 in melanoma cells sensitized these cells to anti-cancer agents known to be metabolized by glucuronidation. Taken together, these novel observations endorse UGTs in melanoma etiology and entail that UGTs must be taken into account for all future melanoma treatment strategies.

Supporting Information

Figure S1 Absence of UGT mRNA expression in metastatic melanoma. RT-PCR analysis of cDNA reverse transcribed from total RNA from the human metastatic melanoma cell lines A375 (A), Lu1205 (B) and SKmel28 (C) using indicated primers sets. GAPDH primers were used as a positive control.

Figure S2 Dose-dependent re-expression of UGT2B7, UGT2B10 and UGT2B15 in WM3211 cells in response to anti-cancer agents. Predesigned Taqman gene expression assays were used to visualize individual UGT expression by real-time PCR following treatment of WM3211 cells with (A) adriamycin or (B) epirubicin. In both cases, UGT2B7, UGT2B10 and UGT2B15 expression was examined following treatment of 0, 0.1, 1.0 or 10 μM of indicated drug 8 hrs post treatment. *indicates different scale for y-axis.

Figure S3 Re-expression of UGT2B7, UGT2B10 and UGT2B15 in A375 cells in response to epirubicin. Predesigned Taqman gene expression assays were used to visualize individual UGT expression by real-time PCR following treatment of A375 cells with epirubicin. Time course of indicated UGT2B expression following epirubicin treatment (100 nM) was examined at 0, 8, 16 and 24 hrs. *indicates different scale for y-axis.

Table S1 Primers used in conventional PCR experiments. Both sense and anti-sense primers used to distinguish individual UGT members being listed along with the size of the amplicon. These primers were used in Figure 1A-D and Figure S1.

(PDF)
Acknowledgments

The authors would like to thank Drs. Sun Yang and Feng Liu for scientific discussions; Angela Garcia for technical support with melanocyte cultures; and Dr. Hung Fan for fostering the development of young scientists.

References

1. Nagar S, Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenomics and cancer. Oncogene 25: 1659–1672.
2. Tyue RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40: 581–616.
3. Dellingger RW, Chen G, Blevis-Primeau AS, Krzeminski J, Amin S, et al. (2007) Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 28: 2412–2418.
4. Basu NK, Kowarova M, Garza A, Kubota S, Saha T, et al. (2005) Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity. Proc Natl Acad Sci U S A 102: 6256–6260.
5. Chouinard S, Yueh MF, Tyue RH, Giton F, Firt J, et al. (2000) Inactivation by UDP-glucuronosyltransferase enzymes: the end of drug signaling: J Steroid Biochem Mol Biol 109: 247–253.
6. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A (2008) Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 73: 611–620.
7. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI (2004) Regulation of UDP-glucuronosyltransferases in the gastrointestinal tract. Toxicol Lett 199: 354–363.
8. Giuliani L, Cioti M, Stoppacchiaro A, Pasquini A, Silvestri I, et al. (2005) UDP-glucuronosyltransferase 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13: 185–191.
9. King CD, Rios GR, Green MD, Trophy TR. (2000) UDP-glucuronosyltransferases. Curr Drug Metab 1: 143–161.
10. Zheng Z, Fang JL, Lazarus P (2002) Glucuronidation: an important mechanism for detoxification of benzo(a)pyrene metabolites in aerodigestive tract cancer. Drug Metab Dispos 30: 397–403.
11. Dellingger RW, Fang JL, Chen G, Weinberg R, Lazarus P (2006) Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10/UGT1A9 isoform. Drug Metab Dispos 34: 945–949.
12. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targets. Nature 453: 851–857.
13. Chen L (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3: 539–550.
14. Meyskens FL Jr, Farmer PJ, Yang S, Anton-Culver H (2007) New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res 174: 191–195.
15. Miller AJ, Mihn MC Jr (2006) Melanoma. N Engl J Med 355: 51–65.
16. Ko JM, Fisher DE. (2011) A new era: melanoma genetics and therapeutics. J Invest Dermatol 127: 224–231.
17. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 845–852.
18. Augustine CK, Yoo JS, Poti A, Yoshimatsu Y, Zigeld PA, et al. (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15: 502–510.
19. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3158–3161.
20. Lal S, Mahajan A, Chen WY, Chowbay B (2010) Pharmacogenomics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11: 115–128.
21. Smalley KS, Sondak VK (2010) Melanoma—an unlikely poster child for pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13: 517–523.
22. Lazard Z, Dzupko K, Fornia Y, Neel P, Lazarovitz J, et al. (1991) Oderant signal termination by olfactory UDP glucuronosyl transferase. Nature 349: 790–793.
23. Chouinard S, Yueh MF, Tyue RH, Giton F, Firt J, et al. (2000) Inactivation by UDP-glucuronosyltransferase enzymes: the end of drug signaling: J Steroid Biochem Mol Biol 109: 247–253.
24. Chen G, Dellingger RW, Gallagher CJ, Sun D, Lazarus P (2000) Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 10: 181–191.
25. Desai AA, Innocenti F, Ratain MJ (2003) UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13: 517–523.
26. Flaherty KT, Puzanov I, Kim KB, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 845–852.
27. Augustine CK, Yoo JS, Poti A, Yoshimatsu Y, Zigeld PA, et al. (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15: 502–510.
28. Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH, et al. (2008) Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology 82: 1–9.
29. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3158–3161.
30. Lal S, Mahajan A, Chen WY, Chowbay B (2010) Pharmacogenomics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11: 115–128.
31. Innocenti F, Iyer I, Ramirez J, Green MD, Ratain MJ (2001) Epipodophyllotoxin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29: 696–692.
32. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, et al. (2007) Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369: 498–513.
33. Zhang H, Patana S, Mackenzie PL, Ishashiro SI, Goldman A, et al. (2012) Human UGT Expression in Insect Cells: The Ratio of Active to Inactive Reconstituent Proteins and the Effects of a C-terminal His-tag on Glucuronidation Kinetics. Drug Metab Dispos 3: 361–370.
34. Nakamura A, Nakajima M, Yamanaka H, Fujisawa R, Yoko T (2008) Expression of UGT1A1 and UGT2B2 mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36: 1461–1464.
35. Buckley DB, Klausen CD (2009) Mechanism of gender-discr etent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. Drug Metab Dispos 37: 834–840.
36. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, et al. (2007) The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Preven 16: 823–828.
37. Saracino MR, Lampe JW (2007) Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention. Nutr Cancer 59: 121–141.
38. Oguri T, Takahashi T, Miotzaki M, Isobe T, Kohno N, et al. (2004) UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 24: 2093–2096.
39. Baubeele A, Preissler I, de Carne Trecesson S, Boidron-Gelle M, Gamelin E, et al. (2011) Iriotestan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer Ther 24: 2093–2096.
40. Ethell BT, Anderson GD, Burchell B (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 65: 1441–1449.
41. Little AS, Smith PD, Cook SJ (2012) Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene.

Author Contributions

Conceived and designed the experiments: RWD FLM. Performed the experiments: RWD HHM ASA PHD. Analyzed the data: RWD HHM ASA PHD. Wrote the paper: RWD FLM.

Re-Expression of UGTs in Melanoma